Concert Pharmaceuticals Inc. buy Quitte
Summary
This prediction ended on 02.05.19 with a price of €9.27. The prediction for Concert Pharmaceuticals Inc. disappointed with a performance of -29.40%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Concert Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | 0.238% | -2.265% | 13.679% | 14.917% |
| iShares Nasdaq 100 | -0.304% | 5.808% | 34.538% | 52.796% |
| iShares Nikkei 225® | 2.271% | 1.577% | 9.436% | 5.432% |
| iShares S&P 500 | -0.296% | 4.447% | 28.577% | 47.257% |
Comments by Quitte for this prediction
In the thread Concert Pharmaceuticals Inc. diskutieren
mal dem Analysten folgen...
Concert Pharma (CNCE)
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Concert Pharma. The company’s shares opened today at $14, close to its 52-week low of $12.33.
Yang noted:
“We do not see earnings as the most meaningful indicator of value for early-stage biotechs. Importantly, Concert is on track to report CTP-543 phase 2 data (4mg and 8mg cohorts) in November. We believe positive data in the 8mg cohort would be incrementally positive as Concert continues to enroll patients in the 12mg cohort of the phase 2 program. 12 mg cohort could be available in 3Q19. We updated our model and adjust our PT from $27 to $26. Reiterate Buy.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.2% and a 47.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
Concert Pharma has an analyst consensus of Strong Buy, with a price target consensus of $26.33.